IL Minn

Research output

Research output per year 1998 2014 2016 2018 2019 2020 2021 2022 2023

• 60 Article
• 3 Review article
• 2 Chapter
• 2 Conference contribution
• 2 More
  • 1 Comment/debate
  • 1 Letter

Research output per year

Research output per year

Search results

• 2023

  First-in-human imaging using [¹¹C]MDTC: a radiotracer targeting the cannabinoid receptor type 2

  Du, Y., Coughlin, J. M., Brosnan, M. K., Chen, A., Shinehouse, L. K., Abdallah, R., Lodge, M. A., Mathews, W. B., Liu, C., Wu, Y., Minn, I., Finley, P., Hall, A. W., Lesniak, W. G., Dannals, R. F., Horti, A. G. & Pomper, M. G., Jul 2023, In: European Journal of Nuclear Medicine and Molecular Imaging. 50, 8, p. 2386-2393 8 p.

  Research output: Contribution to journal › Article › peer-review

  • monodansylthiacadaverine 100%
  • Cannabinoid Receptors 58%
  • Positron-Emission Tomography 31%
  • Brain 16%
  • Microglia 4%

• Imaging Brain Injury in Former National Football League Players

  Rubin, L. H., Du, Y., Sweeney, S. E., O’Toole, R., Thomas, C. L., Zandi, A. G., Shinehouse, L. K., Brosnan, M. K., Nam, H., Burke, M. E., Bureau, S. C., Kilgore, J. J., Yoon, M., Soule, A. R., Lesniak, W. G., Minn, I., Rowe, S. P., Holt, D. P., Hall, A. W., Mathews, W. B., & 6 othersSmith, G. S., Nowinski, C. J., Kassiou, M., Dannals, R. F., Pomper, M. G. & Coughlin, J. M., 2023, (Accepted/In press) In: JAMA Network Open. p. E2340580

  Research output: Contribution to journal › Article › peer-review

  • Football 100%
  • N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamide 98%
  • Brain Injuries 82%
  • Athletes 60%
  • Sports 58%

• Preclinical Evaluation of a New Series of Albumin-Binding ¹⁷⁷Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics

  Boinapally, S., Alati, S., Jiang, Z., Yan, Y., Lisok, A., Singh, R., Lofland, G., Minn, I., Hobbs, R. F., Pomper, M. & Banerjee, S. R., Aug 2023, In: Molecules. 28, 16, 6158.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • antigens 100%
  • albumins 97%
  • low molecular weights 95%
  • Prostate-Specific Antigen 80%
  • tumors 75%
• 2022

  An Improved ²¹¹At-Labeled Agent for PSMA-Targeted a-Therapy

  Mease, R. C., Kang, C. M., Kumar, V., Banerjee, S. R., Minn, I., Brummet, M., Gabrielson, K. L., Feng, Y., Park, A., Kiess, A. P., Sgouros, G., Vaidyanathan, G., Zalutsky, M. R. & Pomper, M. G., Feb 1 2022, In: Journal of Nuclear Medicine. 63, 2, p. 259-267 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Prostate-Specific Antigen 100%
  • Membranes 58%
  • Lutetium 47%
  • Prostatic Neoplasms 38%
  • Tin 34%

• A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents

  Chen, Y., Minn, I., Rowe, S. P., Lisok, A., Chatterjee, S., Brummet, M., Banerjee, S. R., Mease, R. C. & Pomper, M. G., Mar 2022, In: Biomolecules. 12, 3, 405.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fluorescent Dyes 69%
  • Lysine 62%
  • Poly(ethylene Glycol) 52%
  • Urea 51%
  • Pharmacokinetics 49%

• A Unique Core–Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects

  Cheng, B., Ahn, H. H., Nam, H., Jiang, Z., Gao, F. J., Minn, I. & Pomper, M. G., Feb 2022, In: Pharmaceutics. 14, 2, 373.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • glycol-chitosan 100%
  • Neoplasm Genes 62%
  • Glycol 52%
  • Nanoparticles 51%
  • Propionate 43%

• Correction to: Hetero-bivalent agents targeting FAP and PSMA (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 13, (4369-4381), 10.1007/s00259-022-05933-3)

  Boinapally, S., Lisok, A., Lofland, G., Minn, I., Yan, Y., Jiang, Z., Shin, M. J., Merino, V. F., Zheng, L., Brayton, C., Pomper, M. & Banerjee, S. R., Nov 2022, In: European Journal of Nuclear Medicine and Molecular Imaging. 49, 13, p. 4755 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Molecular Imaging 100%
  • Nuclear Medicine 98%
  • Emotions 66%

• Hetero-bivalent agents targeting FAP and PSMA

  Boinapally, S., Lisok, A., Lofland, G., Minn, I., Yan, Y., Jiang, Z., Shin, M. J., Merino, V. F., Zheng, L., Brayton, C., Pomper, M. & Banerjee, S. R., Nov 2022, In: European Journal of Nuclear Medicine and Molecular Imaging. 49, 13, p. 4369-4381 13 p.

  Research output: Contribution to journal › Article › peer-review

  • fibroblast activation protein alpha 100%
  • Prostate-Specific Antigen 58%
  • Membranes 33%
  • Neoplasms 11%
  • Theranostic Nanomedicine 10%

• Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma

  Vaughan, H. J., Zamboni, C. G., Hassan, L. F., Radant, N. P., Jacob, D., Mease, R. C., Minn, I., Tzeng, S. Y., Gabrielson, K. L., Bhardwaj, P., Guo, X., Francisco, D., Pomper, M. G. & Green, J. J., Jul 2022, In: Science Advances. 8, 29, eabo6406.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Theranostic Nanomedicine 100%
  • Nanoparticles 67%
  • Hepatocellular Carcinoma 60%
  • alpha-Fetoproteins 50%
  • Genes 30%
• 2021

  A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile

  Boinapally, S., Ahn, H. H., Cheng, B., Brummet, M., Nam, H., Gabrielson, K. L., Banerjee, S. R., Minn, I. & Pomper, M. G., Dec 2021, In: Scientific reports. 11, 1, 7114.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Prodrugs 100%
  • Prostate-Specific Antigen 92%
  • Membranes 53%
  • Prostatic Neoplasms 35%
  • monomethyl auristatin E 19%

• First-in-human neuroimaging of soluble epoxide hydrolase using [¹⁸F]FNDP PET

  Coughlin, J. M., Slania, S., Du, Y., Shinehouse, L. K., Brosnan, M. K., Azad, B. B., Holt, D. P., Fan, H., Lesniak, W. G., Minn, I., Rowe, S. P., Dannals, R. F., Horti, A. G. & Pomper, M. G., Sep 2021, In: European Journal of Nuclear Medicine and Molecular Imaging. 48, 10, p. 3122-3128 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Epoxide Hydrolases 100%
  • Positron-Emission Tomography 66%
  • Neuroimaging 65%
  • Brain 17%
  • Cerebellar Cortex 14%
  1 Scopus citations

• Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers

  Ahn, H. H., Carrington, C., Hu, Y., Liu, H. W., Ng, C., Nam, H., Park, A., Stace, C., West, W., Mao, H. Q., Pomper, M. G., Ullman, C. G. & Minn, I., Dec 2021, In: Scientific reports. 11, 1, 9733.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nanoparticles 100%
  • Lung Neoplasms 89%
  • Polyethyleneimine 50%
  • Genes 45%
  • Interleukin-12 38%

• Non-invasive delivery of levodopa-loaded nanoparticles to the brain via lymphatic vasculature to enhance treatment of Parkinson’s disease

  Nie, T., He, Z., Zhu, J., Chen, K., Howard, G. P., Pacheco-Torres, J., Minn, I., Zhao, P., Bhujwalla, Z. M., Mao, H. Q., Liu, L. & Chen, Y., Aug 2021, In: Nano Research. 14, 8, p. 2749-2761 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Parkinson disease 100%
  • dopamine 64%
  • Nanoparticles 62%
  • delivery 60%
  • brain 60%

• Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low- Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer

  Banerjee, S. R., Lisok, A., Minn, I., Josefsson, A., Kumar, V., Brummet, M., Boinapally, S., Brayton, C., Mease, R. C., Sgouros, G., Hobbs, R. F. & Pomper, M. G., Jul 1 2021, In: Journal of Nuclear Medicine. 62, 7, p. 980-988 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiopharmaceuticals 100%
  • Molecular Weight 69%
  • Prostatic Neoplasms 65%
  • Kidney 14%
  • Prostate-Specific Antigen 14%

• Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [¹¹¹In]In-XYIMSR-01 for phase I regulatory approval

  De Silva, R. A., Gorin, M. A., Mease, R. C., Minn, I., Lisok, A., Plyku, D., Nimmagadda, S., Allaf, M. E., Yang, X., Sgouros, G., Rowe, S. P. & Pomper, M. G., May 30 2021, In: Journal of Labelled Compounds and Radiopharmaceuticals. 64, 6, p. 243-250 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Carbonic Anhydrase IX 100%
  • Dosimetry 91%
  • Dose 51%
  • Pharmacopoeias 28%
  • Clinical Trials, Phase I 27%

• Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery

  Liu, H. W., Hu, Y., Ren, Y., Nam, H., Santos, J. L., Ng, S., Gong, L., Brummet, M., Carrington, C. A., Ullman, C. G., Pomper, M. G., Minn, I. & Mao, H. Q., Jul 7 2021, In: ACS Applied Materials and Interfaces. 13, 26, p. 30326-30336 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Purification 100%
  • DNA 91%
  • Nanoparticles 87%
  • Filtration 76%
  • Flow 57%

• Synthesis and preliminary evaluation of ²¹¹At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer

  Vaidyanathan, G., Mease, R. C., Minn, I., Choi, J., Chen, Y., Shallal, H., Kang, C. M., McDougald, D., Kumar, V., Pomper, M. G. & Zalutsky, M. R., Mar 1 2021, In: Nuclear Medicine and Biology. 94-95, p. 67-80 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Alpha Particles 100%
  • Prostate-Specific Antigen 70%
  • Prostatic Neoplasms 54%
  • Membranes 41%
  • Ligands 16%

• Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors

  Rogers, O. C., Rosen, D. M., Antony, L., Harper, H. M., Das, D., Yang, X., Minn, I., Mease, R. C., Pomper, M. G. & Denmeade, S. R., Dec 2021, In: Scientific reports. 11, 1, 14925.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Prostate-Specific Antigen 100%
  • Urea 92%
  • Prostatic Neoplasms 77%
  • Membranes 58%
  • Proteins 35%

• Triptolide: Reflections on two decades of research and prospects for the future

  Tong, L., Zhao, Q., Datan, E., Lin, G. Q., Minn, I., Pomper, M. G., Yu, B., Romo, D., He, Q. L. & Liu, J. O., Apr 2021, In: Natural Product Reports. 38, 4, p. 843-860 18 p.

  Research output: Contribution to journal › Review article › peer-review

  • Triptolide 100%
  • triptolide 87%
  • Reflection 45%
  • Diterpene Triepoxide 31%
  • Tripterygium 21%
  1 Scopus citations
• 2020

  (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as a Novel PSMA Targeting Scaffold for Prostate Cancer Imaging

  Duan, X., Liu, F., Kwon, H., Byun, Y., Minn, I., Cai, X., Zhang, J., Pomper, M. G., Yang, Z., Xi, Z. & Yang, X., Apr 9 2020, In: Journal of medicinal chemistry. 63, 7, p. 3563-3576 14 p.

  Research output: Contribution to journal › Article › peer-review

  • propionic acid 100%
  • Prostate-Specific Antigen 77%
  • Antigen 63%
  • Prostatic Neoplasms 59%
  • Membranes 44%
  6 Scopus citations

• A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia

  Datan, E., Minn, I., Xu, P., He, Q. L., Ahn, H. H., Yu, B., Pomper, M. G. & Liu, J. O., Sep 25 2020, In: iScience. 23, 9, 101536.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • triptolide 100%
  • Cell Hypoxia 83%
  • Glucose 41%
  • Lead 30%
  • Neoplasms 21%

• Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer

  Shen, C. J., Minn, I., Hobbs, R. F., Chen, Y., Josefsson, A., Brummet, M., Banerjee, S. R., Brayton, C. F., Mease, R. C., Pomper, M. G. & Kiess, A. P., 2020, In: Theranostics. 10, 7, p. 2888-2896 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiopharmaceuticals 100%
  • Prostate-Specific Antigen 85%
  • Prostatic Neoplasms 65%
  • Membranes 49%
  • Urinalysis 24%
  7 Scopus citations

• Design and synthesis of a novel BODIPY-labeled PSMA inhibitor

  Son, S. H., Kwon, H., Ahn, H. H., Nam, H., Kim, K., Nam, S. J., Choi, D., Ha, H., Minn, I. & Byun, Y., Feb 1 2020, In: Bioorganic and Medicinal Chemistry Letters. 30, 3, 126894.

  Research output: Contribution to journal › Article › peer-review

  • Prostate-Specific Antigen 63%
  • Antigen 51%
  • Membranes 36%
  • Protein 25%
  • Prostatic Neoplasms 19%
  3 Scopus citations

• High Availability of the a7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using 18F-ASEM PET

  Coughlin, J. M., Rubin, L. H., Du, Y., Rowe, S. P., Crawford, J. L., Rosenthal, H. B., Frey, S. M., Marshall, E. S., Shinehouse, L. K., Chen, A., Speck, C. L., Wang, Y., Lesniak, W. G., Minn, I., Bakker, A., Kamath, V., Smith, G. S., Albert, M. S., Azad, B. B., Dannals, R. F., & 3 othersHorti, A., Wong, D. F. & Pomper, M. G., Mar 1 2020, In: Journal of Nuclear Medicine. 61, 3, p. 423-426 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 3-(1,4-diazabicyclo(3.2.2)nonan-4-yl)-6-fluorodibenzo(b,d)thiophene 5,5-dioxide 100%
  • Nicotinic Receptors 48%
  • Cognitive Dysfunction 35%
  • Brain 21%
  • Prodromal Symptoms 9%
  3 Scopus citations

• Novel β- And γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen

  Kim, K., Kwon, H., Barinka, C., Motlova, L., Nam, S., Choi, D., Ha, H., Nam, H., Son, S. H., Minn, I., Pomper, M. G., Yang, X., Kutil, Z. & Byun, Y., Mar 26 2020, In: Journal of medicinal chemistry. 63, 6, p. 3261-3273 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Prostate-Specific Antigen 100%
  • Antigen 81%
  • Amino Acids 68%
  • Membranes 58%
  • Acid 22%
  3 Scopus citations

• PET imaging of soluble epoxide hydrolase in non-human primate brain with [¹⁸F]FNDP

  Du, Y., Minn, I., Foss, C., Lesniak, W. G., Hu, F., Dannals, R. F., Pomper, M. G. & Horti, A. G., 2020, In: EJNMMI Research. 10, 1, 67.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Epoxide Hydrolases 100%
  • 1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-urea 85%
  • Papio 73%
  • Primates 66%
  • Positron-Emission Tomography 66%
  2 Scopus citations

• Preclinical evaluation of ^203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer

  Banerjee, S. R., Minn, I., Kumar, V., Josefsson, A., Lisok, A., Brummet, M., Chen, J., Kiess, A. P., Baidoo, K., Brayton, C., Mease, R. C., Brechbiel, M., Sgouros, G., Hobbs, R. F. & Pomper, M. G., Jan 2020, In: Journal of Nuclear Medicine. 61, 1, p. 80-88 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiopharmaceuticals 100%
  • Prostate-Specific Antigen 85%
  • Molecular Weight 69%
  • Prostatic Neoplasms 65%
  • Membranes 49%
  13 Scopus citations

• Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1′ region

  Kwon, H., Lim, H., Ha, H., Choi, D., Son, S. H., Nam, H., Minn, I. & Byun, Y., Nov 2020, In: Bioorganic Chemistry. 104, 104304.

  Research output: Contribution to journal › Article › peer-review

  • Structure-Activity Relationship 100%
  • Prostate-Specific Antigen 87%
  • Antigen 71%
  • Amino Acids 59%
  • Membranes 50%
  1 Scopus citations
• 2019

  ¹⁷⁷Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy

  Banerjee, S. R., Kumar, V., Lisok, A., Chen, J., Minn, I., Brummet, M., Boinapally, S., Cole, M., Ngen, E., Wharram, B., Brayton, C., Hobbs, R. F. & Pomper, M. G., Nov 1 2019, In: European Journal of Nuclear Medicine and Molecular Imaging. 46, 12, p. 2545-2557 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiopharmaceuticals 100%
  • Prostate-Specific Antigen 85%
  • Molecular Weight 69%
  • Membranes 49%
  • PC-3 Cells 20%
  8 Scopus citations

• Compositional control of pDNA/lPEI nanoparticles using flash nanocomplexation to improve in vivo transfection efficiency and biocompatibility

  Hu, Y., Liu, H. W., Minn, I., Pomper, M. & Mao, H. Q., 2019, Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, p. 383 1 p. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; vol. 40).

  Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

  • Polyetherimides 100%
  • Biocompatibility 81%
  • DNA 68%
  • Nanoparticles 65%
  • Transfection 57%

• Design and synthesis of dye-conjugated hepsin inhibitors

  Kim, K., Kwon, H., Choi, D., Lim, T., Minn, I., Son, S. H. & Byun, Y., Aug 2019, In: Bioorganic Chemistry. 89, 102990.

  Research output: Contribution to journal › Article › peer-review

  • hepsin 100%
  • Coloring Agents 45%
  • Leu-Arg 32%
  • Dipeptide 18%
  • Biological Marker 16%
  3 Scopus citations

• Enhancing CAR T-cell therapy through cellular imaging and radiotherapy

  Minn, I., Rowe, S. P. & Pomper, M. G., Aug 2019, In: The Lancet Oncology. 20, 8, p. e443-e451

  Research output: Contribution to journal › Review article › peer-review

  • Chimeric Antigen Receptors 100%
  • Cell- and Tissue-Based Therapy 70%
  • Radiotherapy 51%
  • T-Lymphocytes 45%
  • Neoplasms 15%
  23 Scopus citations

• Flash nanocomplexation as a scalable production method for therapeutic pdna/lpei nanoparticles

  Liu, H. W., Hu, Y., Minn, I., Pomper, M. & Mao, H. Q., 2019, Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, p. 301 1 p. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; vol. 40).

  Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

  • Nanoparticles 100%
  • Polyethyleneimine 76%
  • DNA 69%
  • Nanoparticle 50%
  • Plasmids 45%

• Imaging CAR T cell therapy with PSMA-targeted positron emission tomography

  Minn, I., Huss, D. J., Ahn, H. H., Chinn, T. M., Park, A., Jones, J., Brummet, M., Rowe, S. P., Sysa-Shah, P., Du, Y., Levitsky, H. I. & Pomper, M. G., 2019, In: Science Advances. 5, 7, eaaw5096.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Prostate-Specific Antigen 75%
  • Cell- and Tissue-Based Therapy 70%
  • Positron-Emission Tomography 69%
  • T-Lymphocytes 45%
  29 Scopus citations

• Kinetic Control in Assembly of Plasmid DNA/Polycation Complex Nanoparticles

  Hu, Y., He, Z., Hao, Y., Gong, L., Pang, M., Howard, G. P., Ahn, H. H., Brummet, M. E., Chen, K., Liu, H. W., Ke, X., Zhu, J., Anderson, C. F., Cui, H., Ullman, C. G., Carrington, C. A., Pomper, M. G., Seo, J. H., Mittal, R., Minn, I., & 1 othersMao, H. Q., Apr 30 2019, In: ACS Nano. 13, 9, p. 10161-10178 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • plasmids 100%
  • Polycationic Polymer 82%
  • DNA 73%
  • Nanoparticles 69%
  • deoxyribonucleic acid 64%
  15 Scopus citations

• PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R)

  Horti, A. G., Naik, R., Foss, C. A., Minn, I., Misheneva, V., Du, Y., Wang, Y., Mathews, W. B., Wu, Y., Hall, A., LaCourse, C., Ahn, H. H., Nam, H., Lesniak, W. G., Valentine, H., Pletnikova, O., Troncoso, J. C., Smith, M. D., Calabresi, P. A., Savonenko, A. V., & 3 othersDannals, R. F., Pletnikov, M. V. & Pomper, M. G., Jan 29 2019, In: Proceedings of the National Academy of Sciences of the United States of America. 116, 5, p. 1686-1691 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Macrophage Colony-Stimulating Factor Receptors 100%
  • Macrophage Colony-Stimulating Factor 80%
  • Microglia 67%
  • Alzheimer Disease 51%
  • Demyelinating Diseases 46%
  44 Scopus citations
• 2018

  ¹⁸F-XTRA PET for enhanced imaging of the extrathalamic α4β2 nicotinic acetylcholine receptor

  Coughlin, J. M., Slania, S., Du, Y., Rosenthal, H. B., Lesniak, W. G., Minn, I., Smith, G. S., Dannals, R. F., Kuwabara, H., Wong, D. F., Wang, Y., Horti, A. G. & Pomper, M. G., Oct 1 2018, In: Journal of Nuclear Medicine. 59, 10, p. 1603-1608 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nicotinic Receptors 100%
  • Hippocampus 72%
  • Thalamus 44%
  • Brain 44%
  • Neuroimaging 41%
  4 Scopus citations

• Biodistribution and radiation dosimetry of 124I-DPA-713, a PET radiotracer for macrophage-associated inflammation

  Foss, C. A., Plyku, D., Ordonez, A. A., Sanchez-Bautista, J., Rosentha, H. B., Minn, I., Lodge, M. A., Pomper, M. G., Sgouros, G. & Jain, S. K., Nov 1 2018, In: Journal of Nuclear Medicine. 59, 11, p. 1751-1756 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamide 100%
  • Radiometry 71%
  • Macrophages 33%
  • Inflammation 28%
  • Hepatobiliary Elimination 24%
  8 Scopus citations

• Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors

  Vaidyanathan, G., Kang, C. M., McDougald, D., Minn, I., Brummet, M., Pomper, M. G. & Zalutsky, M. R., Jul 1 2018, In: Nuclear Medicine and Biology. 62-63, p. 18-30 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Microvilli 100%
  • Prostate-Specific Antigen 94%
  • Membranes 54%
  • Enzymes 50%
  • Kidney 49%
  5 Scopus citations

• Follicle-stimulating hormone receptor in gynecological cancers

  Chung, H. H., Lee, J. C. & Minn, I., Jan 1 2018, In: Molecular and Cellular Toxicology. 14, 1

  Research output: Contribution to journal › Review article › peer-review

  • Follicle Stimulating Hormone 100%
  • FSH Receptors 93%
  • cancer 58%
  • Neoplasms 20%
  • human FSHR protein 13%
  1 Scopus citations

• Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo

  Zhang, H. K., Chen, Y., Kang, J., Lisok, A., Minn, I., Pomper, M. & Boctor, E., Sep 2018, In: Journal of biophotonics. 11, 9, e201800021.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Photoacoustic effect 100%
  • Antigens 86%
  • antigens 81%
  • Prostate-Specific Antigen 65%
  • cancer 59%
  12 Scopus citations

• Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer

  Banerjee, S. R., Song, X., Yang, X., Minn, I., Lisok, A., Chen, Y., Bui, A., Chatterjee, S., Chen, J., van Zijl, P. C. M., McMahon, M. T. & Pomper, M. G., May 17 2018, In: Chemistry - A European Journal. 24, 28, p. 7235-7242 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Salicylic acid 100%
  • Magnetic Resonance Imaging 62%
  • Contrast Medium 61%
  • Imaging techniques 41%
  • Magnetic resonance 28%
  5 Scopus citations

• The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [¹⁸F]ASEM

  Coughlin, J. M., Du, Y., Rosenthal, H. B., Slania, S., Min Koo, S., Park, A., Solomon, G., Vranesic, M., Antonsdottir, I., Speck, C. L., Rootes-Murdy, K., Lerner, A., Rowe, S. P., Wang, Y., Lesniak, W. G., Minn, I., Bakker, A., Smith, G. S., Dannals, R. F., Kuwabara, H., & 3 othersHorti, A., Wong, D. F. & Pomper, M. G., Jan 15 2018, In: NeuroImage. 165, p. 118-124 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 3-(1,4-diazabicyclo(3.2.2)nonan-4-yl)-6-fluorodibenzo(b,d)thiophene 5,5-dioxide 100%
  • alpha7 Nicotinic Acetylcholine Receptor 74%
  • Healthy Aging 54%
  • Positron-Emission Tomography 40%
  • Elderly 12%
  15 Scopus citations
• 2017

  A PSMA-targeted theranostic agent for photodynamic therapy

  Chen, Y., Chatterjee, S., Lisok, A., Minn, I., Pullambhatla, M., Wharram, B., Wang, Y., Jin, J., Bhujwalla, Z. M., Nimmagadda, S., Mease, R. C. & Pomper, M. G., Feb 1 2017, In: Journal of Photochemistry and Photobiology B: Biology. 167, p. 111-116 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Theranostic Nanomedicine 100%
  • antigens 96%
  • Photochemotherapy 81%
  • Prostate-Specific Antigen 77%
  • therapy 72%
  26 Scopus citations

• Imaging of glial cell activation and white matter integrity in brains of active and recently retired national football league players

  Coughlin, J. M., Yuchuanwang, Y., Minn, I., Bienko, N., Ambinder, E. B., Xu, X., Peters, M. E., Dougherty, J. W., Vranesic, M., Koo, S. M., Ahn, H. H., Lee, M., Cottrell, C., Sair, H. I., Sawa, A., Munro, C. A., Nowinski, C. J., Dannals, R. F., Lyketsos, C. G., Kassiou, M., & 5 othersSmith, G., Caffo, B., Mori, S., Guilarte, T. R. & Pomper, M. G., Jan 1 2017, In: JAMA Neurology. 74, 1, p. 67-74 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Football 100%
  • White Matter 77%
  • Neuroglia 75%
  • N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamide 50%
  • Brain 41%
  79 Scopus citations
• 2016

  (2S)-2-(3-(1-carboxy-5-(4-²¹¹At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy

  Kiess, A. P., Minn, I., Vaidyanathan, G., Hobbs, R. F., Josefsson, A., Shen, C., Brummet, M., Chen, Y., Choi, J., Koumarianou, E., Baidoo, K., Brechbiel, M. W., Mease, R. C., Sgouros, G., Zalutsky, M. R. & Pomper, M. G., Oct 1 2016, In: Journal of Nuclear Medicine. 57, 10, p. 1569-1575 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 2-(3-(1-carboxy-5-(4-astatobenzamido)pentyl)ureido)pentanedioic acid 100%
  • Radiopharmaceuticals 46%
  • Prostate-Specific Antigen 39%
  • Membranes 23%
  • mouse PSMA protein 16%
  59 Scopus citations

• [⁶⁴Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma

  Minn, I., Koo, S. M., Lee, H. S., Brummet, M., Rowe, S. P., Gorin, M. A., Sysa-Shah, P., Lewis, W. D., Ahn, H. H., Wang, Y., Banerjee, S. R., Mease, R. C., Nimmagadda, S., Allaf, M. E., Pomper, M. G. & Yang, X., 2016, In: Oncotarget. 7, 35, p. 56471-56479 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Carbonic Anhydrase IX 100%
  • Renal Cell Carcinoma 64%
  • Positron-Emission Tomography 62%
  • Ligands 47%
  • Neoplasms 21%
  29 Scopus citations

• ^18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase

  Horti, A. G., Wang, Y., Minn, I., Lan, X., Wang, J., Koehler, R. C., Alkayed, N. J., Dannals, R. F. & Pomper, M. G., Nov 1 2016, In: Journal of Nuclear Medicine. 57, 11, p. 1817-1822 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Epoxide Hydrolases 100%
  • Papio 33%
  • Brain 16%
  • Radioactivity 10%
  • Mouse Ephx2 protein 10%
  9 Scopus citations

• Critical Length of PEG Grafts on lPEI/DNA Nanoparticles for Efficient in Vivo Delivery

  Williford, J. M., Archang, M. M., Minn, I., Ren, Y., Wo, M., Vandermark, J., Fisher, P. B., Pomper, M. G. & Mao, H. Q., Apr 11 2016, In: ACS Biomaterials Science and Engineering. 2, 4, p. 567-578 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Grafts 100%
  • Polyethylene glycols 98%
  • DNA 78%
  • Nanoparticles 75%
  • Poly(ethylene Glycol) 60%
  32 Scopus citations

• Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands

  Subedi, M., Minn, I., Chen, J., Kim, Y. H., Ok, K., Jung, Y. W., Pomper, M. G. & Byun, Y., Aug 8 2016, In: European Journal of Medicinal Chemistry. 118, p. 208-218 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • hepsin 100%
  • Prostate-Specific Antigen 56%
  • Antigen 46%
  • Ligands 39%
  • Membranes 32%
  12 Scopus citations